Xilio Therapeutics (XLO) Stock Price, News & Analysis

Company Overview

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.

Key Stats

• Today's Range: $0.72 to $0.76
• 50-Day Range: $0.65 to $0.75
• 52-Week Range: $0.62 to $1.70
• Volume: 963,069 shs
• Average Volume: 2.01 million shs
• Market Capitalization: $38.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Buy

Xilio Therapeutics Stock Analysis - MarketRank™

Xilio Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 707th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Xilio Therapeutics has a consensus price target of $3.00, representing about 302.1% upside from its current price of $0.75.

Amount of Analyst Coverage

Xilio Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.14) to ($0.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xilio Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xilio Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xilio Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.46% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Xilio Therapeutics has recently increased by 12.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xilio Therapeutics does not currently pay a dividend.

Dividend Growth

Xilio Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.46% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in Xilio Therapeutics has recently increased by 12.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for XLO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Xilio Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $72,977.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Xilio Therapeutics is held by insiders.

Percentage Held by Institutions

54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XLO Stock Analysis - Frequently Asked Questions

How have XLO shares performed this year?

Xilio Therapeutics' stock was trading at $0.9550 on January 1st, 2025. Since then, XLO shares have decreased by 21.9% and is now trading at $0.7460.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.08. The firm had revenue of $8.21 million for the quarter, compared to the consensus estimate of $8.21 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 399.15% and a negative net margin of 374.79%.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

Who are Xilio Therapeutics' major shareholders?

Top institutional shareholders of Xilio Therapeutics include Bridgeway Capital Management LLC (0.11%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Rene Russo, James Samuel Shannon, Christopher James Frankenfield and Kevin M Brennan.
View institutional ownership trends.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xilio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and atai Life Sciences (ATAI).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XLO
• CIK: 1840233
• Web: www.xiliotx.com
• Phone: 857-524-2466
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xilio Therapeutics: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +300.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.24 million
• Net Margins: -374.79%
• Pretax Margin: -374.79%
• Return on Equity: -399.15%
• Return on Assets: -58.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.32
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: $6.34 million
• Price / Sales: 6.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 1.88

Miscellaneous

• Outstanding Shares: 51,830,000
• Free Float: 48,563,000
• Market Cap: $38.87 million
• Optionable: Not Optionable
• Beta: -0.14